{"corpus_id":36343021,"paper_sha":"56c47480d6a809a241cae2033be8aa68c5552757","doi":"10.1200/JCO.2006.08.5696","arxiv_id":null,"pmid":17687155,"pmcid":null,"mag_id":2148968593,"dblp_id":null,"acl_id":null,"title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.","year":2007,"publication_date":"2007-08-10","venue":"Journal of Clinical Oncology","journal":{"name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pages":"\n          3503-10\n        ","volume":"25 23"},"journal_issn":null,"journal_title":null,"publication_types":["Study","JournalArticle"],"pubmed_pub_types":["Journal Article","Multicenter Study","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":29,"citation_count":1023,"influential_citation_count":53,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Blood Transfusion","mj":false,"ui":"D001803"},{"d":"Cohort Studies","mj":false,"ui":"D015331"},{"d":"Cytogenetics","mj":false,"ui":"D003582"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Follow-Up Studies","mj":false,"ui":"D005500"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Karyotyping","mj":false,"ui":"D007621"},{"d":"Leukemia","mj":false,"qs":[{"q":"diagnosis","mj":true,"ui":"Q000175"},{"q":"etiology","mj":true,"ui":"Q000209"}],"ui":"D007938"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Myelodysplastic Syndromes","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"pathology","mj":true,"ui":"Q000473"}],"ui":"D009190"},{"d":"Neoplasm Staging","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D009367"},{"d":"Prognosis","mj":false,"ui":"D011379"},{"d":"Time Factors","mj":false,"ui":"D013997"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"}],"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"PURPOSE: The aims of this study were to identify the most significant prognostic factors in myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and their changes in time and to develop a dynamic model for predicting survival and leukemic evolution that can be applied at any time during the course of the disease. PATIENTS AND METHODS: We studied a learning cohort of 426 MDS patients diagnosed at the Department of Hematology, San Matteo Hospital, Pavia, Italy, between 1992 and 2004, and a validation cohort of 739 patients diagnosed at the Heinrich-Heine-University Hospital, Düsseldorf, Germany, between 1982 and 2003. All patients were reclassified according to WHO criteria. Univariable and multivariable analyses were performed using Cox models with time-dependent covariates. RESULTS: The most important variables for the prognostic model were WHO subgroups, karyotype, and transfusion requirement. We defined a WHO classification-based prognostic scoring system (WPSS) that was able to classify patients into five risk groups showing different survivals (median survival from 12 to 103 months) and probabilities of leukemic evolution (P < .001). WPSS was shown to predict survival and leukemia progression at any time during follow-up (P < .001), and its prognostic value was confirmed in the validation cohort. CONCLUSION: WPSS is a dynamic prognostic scoring system that provides an accurate prediction of survival and risk of leukemic evolution in MDS patients at any time during the course of their disease. This time-dependent system seems particularly useful in lower risk patients and may be used for implementing risk-adapted treatment strategies.","claims":[{"public_id":"cl_7d9a165ef88d11b91c8c2987cc2adbcb","status":"active","text":"The WHO classification-based prognostic scoring system (WPSS) classifies patients into five risk groups showing different survivals (median survival from 12 to 103 months) and probabilities of leukemic evolution (P < .001).","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7d9a165ef88d11b91c8c2987cc2adbcb"},{"public_id":"cl_51869ff56362798e2bcd66c60260ef31","status":"active","text":"WHO subgroups, karyotype, and transfusion requirement are the most important variables for the prognostic model in myelodysplastic syndromes.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_51869ff56362798e2bcd66c60260ef31"},{"public_id":"cl_970bcc6c830a76d179f5427f0d57cb9d","status":"active","text":"WPSS is a dynamic prognostic scoring system that provides accurate prediction of survival and risk of leukemic evolution in MDS patients at any time during the course of their disease.","confidence":0.9,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_970bcc6c830a76d179f5427f0d57cb9d"},{"public_id":"cl_4fae2d15a5120907806cb11e86663e1b","status":"active","text":"WPSS predicts survival and leukemia progression at any time during follow-up (P < .001), and its prognostic value was confirmed in a validation cohort of 739 patients.","confidence":0.95,"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4fae2d15a5120907806cb11e86663e1b"}],"concepts":[{"public_id":"co_070309d58f1c085e8f7c1903526f82ab","status":"active","name":"WPSS","description":"WHO classification-based prognostic scoring system developed to predict survival and leukemic evolution in MDS patients.","types":["scoring system","prognostic model"],"aliases":["WHO classification-based prognostic scoring system"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_070309d58f1c085e8f7c1903526f82ab"},{"public_id":"co_14ab66b4f9f8804e430f1a0eefc83c41","status":"active","name":"five risk groups","description":"The five risk categories defined by WPSS that stratify MDS patients by survival and leukemic evolution probability.","types":["risk stratification"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_14ab66b4f9f8804e430f1a0eefc83c41"},{"public_id":"co_5ceb8c29afeb1cd926e5d1a85372758f","status":"active","name":"WHO subgroups","description":"The World Health Organization classification subgroups used to categorize myelodysplastic syndromes patients.","types":["classification"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5ceb8c29afeb1cd926e5d1a85372758f"},{"public_id":"co_60126be36d22bda3df07541f9228a209","status":"active","name":"median survival","description":"The median survival time across WPSS risk groups, ranging from 12 to 103 months.","types":["outcome measure"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_60126be36d22bda3df07541f9228a209"},{"public_id":"co_6757cc81a4ce21b8e2a92f0ed3bd8394","status":"active","name":"transfusion requirement","description":"Whether a patient requires blood transfusions, used as a time-dependent prognostic variable.","types":["clinical feature"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6757cc81a4ce21b8e2a92f0ed3bd8394"},{"public_id":"co_6f8428baa07aa116ae4ce44516e60ae3","status":"active","name":"survival","description":"Overall survival of MDS patients predicted by WPSS at any time during follow-up.","types":["outcome"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6f8428baa07aa116ae4ce44516e60ae3"},{"public_id":"co_7f2ce7084db3f83b771403071ad14ffd","status":"active","name":"validation cohort","description":"A separate cohort of 739 MDS patients from Düsseldorf used to confirm the prognostic value of WPSS.","types":["study cohort"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7f2ce7084db3f83b771403071ad14ffd"},{"public_id":"co_ab8746738098166efae3d4c16ea8263d","status":"active","name":"karyotype","description":"The chromosomal characteristics of MDS patients, used as a prognostic factor in the model.","types":["biomarker"],"aliases":[],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ab8746738098166efae3d4c16ea8263d"},{"public_id":"co_d6fea953987d94f9dc714ef28977b509","status":"active","name":"myelodysplastic syndromes","description":"Hematologic disorders characterized by bone marrow failure and risk of leukemic transformation, studied in this paper.","types":["condition"],"aliases":["MDS"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d6fea953987d94f9dc714ef28977b509"},{"public_id":"co_decb6e102ab6d4cf8de20308495a5398","status":"active","name":"dynamic prognostic scoring system","description":"A scoring system that accounts for changes in prognostic factors over time, applicable at any point during disease course.","types":["method"],"aliases":["time-dependent prognostic system"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_decb6e102ab6d4cf8de20308495a5398"},{"public_id":"co_ff895d7fe7ebf8cd30c4f5798a5dfccb","status":"active","name":"leukemic evolution","description":"The progression of MDS to acute leukemia, used as an endpoint in the prognostic model.","types":["outcome"],"aliases":["leukemic evolution probability"],"contributors":[{"id":32,"public_id":"7c402c1b98","public_label":"뀨 (7c402c1b98)","roles":["extraction"],"url":"https://sah.borca.ai/u/7c402c1b98"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ff895d7fe7ebf8cd30c4f5798a5dfccb"}],"external_ids":{"DOI":"10.1200/JCO.2006.08.5696","ArXiv":null,"PubMed":17687155,"PubMedCentral":null,"MAG":2148968593,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/36343021","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":637455,"paper_uid":"63fccccd-2bd8-45f2-bb32-00853239839a","canonical_identity":{"paper_id":637455,"paper_uid":"63fccccd-2bd8-45f2-bb32-00853239839a","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/36343021"}